Additional Relevant Details After 8 weeks, in the tiotropium+olodaterol Respimat combined with exercise training arm, exercise capacity in people with moderate to severe COPD significantly increased by 45.8 percent (p<0.001) compared to those receiving placebo with no exercise training (356 vs. 244 seconds respectively).Additional PHYSACTO results showed that even without exercise training, there was a significant improvement (29.2 percent; p<0.05) in exercise capacity in the tiotropium+olodaterol Respimat arm compared to placebo (315 vs. 244 seconds respectively).2 Exercise capacity was measured by the length of time people with COPD could walk in an Endurance Shuttle Walking Test.2 This measures how far someone can walk at a standard speed without stopping for a rest.6 Furthermore, tiotropium+olodaterol Respimat was shown to reduce shortness of breath (dyspnoea) associated with physical activity, compared to placebo.1